Epigenomics AG

  • WKN: A11QW5
  • ISIN: DE000A11QW50
  • Land: Deutschland

Nachricht vom 22.01.2018 | 16:33

Epigenomics AG: Release according to Article 40, Section 1 of the WpHG [the German Securities Trading Act] with the objective of Europe-wide distribution

Epigenomics AG

22.01.2018 / 16:33
Dissemination of a Voting Rights Announcement transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.


Notification of Major Holdings

1. Details of issuer
Epigenomics AG
Geneststraße 5
10829 Berlin
Germany

2. Reason for notification
  Acquisition/disposal of shares with voting rights
  Acquisition/disposal of instruments
  Change of breakdown of voting rights
X Other reason:
Voluntary Notification / Restructuring of group shareholdings in Epigenomics

3. Details of person subject to the notification obligation
Name: City and country of registered office:
Biochain Institute, Inc. Newark, CA 94560
United States of America (USA)

4. Names of shareholder(s)
holding directly 3% or more voting rights, if different from 3.
 

5. Date on which threshold was crossed or reached:
05 Jan 2018

6. Total positions
  % of voting rights attached to shares
(total of 7.a.)
% of voting rights through instruments
(total of 7.b.1 + 7.b.2)
total of both in %
(7.a. + 7.b.)
total number of voting rights of issuer
Resulting situation 4.67 % % 4.67 % 24014360
Previous notification 4.67 % % 4.67 % /

7. Notified details of the resulting situation
a. Voting rights attached to shares (Sec.s 33, 34 WpHG)
ISIN absolute in %
  direct
(Sec. 33 WpHG)
indirect
(Sec. 34 WpHG)
direct
(Sec. 33 WpHG)
indirect
(Sec. 34 WpHG)
DE000A11QW50 1120685 4.67 % %
Total 1120685 4.67 %

b.1. Instruments according to Sec. 38 para. 1 No. 1 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Voting rights absolute Voting rights in %
%
    Total %

b.2. Instruments according to Sec. 38 para. 1 No. 2 WpHG
Type of instrument Expiration or maturity date Exercise or conversion period Cash or physical settlement Voting rights absolute Voting rights in %
%
      Total %

8. Information in relation to the person subject to the notification obligation
  Person subject to the notification obligation is not controlled and does itself not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer (1.).
  Full chain of controlled undertakings starting with the ultimate controlling natural person or legal entity:

Name % of voting rights (if at least held 3% or more) % of voting rights through instruments (if at least held 5% or more) Total of both (if at least held 5% or more)
 

9. In case of proxy voting according to Sec. 34 para. 3 WpHG

Date of general meeting:
Holding position after general meeting: % (equals voting rights)

10. Other explanatory remarks:
Globetrotter(BVI) Holdings, Ltd. as well as the group companies controlling Biochain Institute, Inc. were dissolved with effect as of 5 January 2018. 1,120,685 shares in Epigenomics were acquired by Biochain Institute, Inc. as a result of Globetrotter(BVI)Holdings,Ltd. being dissolved. 



22.01.2018 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

GBC-Fokusbox

Hohes Kurspotenzial: „Attraktiver „Value-add“-Immobilienspezialist

Die Coreo AG führt derzeit eine Bezugsrechtskapitalerhöhung durch, in deren Rahmen ein Bruttoemissionserlös von bis zu 16 Mio. € angestrebt wird. Der Liquiditätserlös soll zum Erwerb von Gewerbe- und Wohnimmobilien für den Geschäftsbereich „Value Add“ verwendet werden. Derzeit, also pre money, verfügt die Gesellschaft über ein prognostiziertes NAV (auf Grundlage von GBC-Berechnungen) von 2,40 €. Für das laufende und kommende Geschäftsjahr rechnen wir mit einem spürbaren Ertrags- und Ergebnisanstieg. Neben der Steigerung von Mieterträgen sollte die Gesellschaft im nennenswerten Umfang Veräußerungserlöse erzielen sowie stille Reserven aufdecken. Auf Basis unseres DCF-Bewertungsmodells (post money) haben wir ein Kursziel von 3,10 € ermittelt. Auf Basis des aktuellen Kurses sowie des Platzierungspreises im Rahmen der Kapitalerhöhung von 1,60 € je Aktie lautet unserer Einschätzung KAUFEN.“

News im Fokus

RWE Aktiengesellschaft: Geplante Umwandlung der Vorzugsaktien in Stammaktien

13. Dezember 2018, 13:01

Aktueller Webcast

Douglas GmbH

FY 2017/18 financial results

11. Dezember 2018

Aktuelle Research-Studie

Manz AG

Original-Research: Manz AG (von Montega AG): Kaufen

14. Dezember 2018